Zhitong Finance App News, Fosun Pharmaceutical (02196.HK) issued an announcement. Recently, the company's holding subsidiary Fosun Pharmaceutical (Xuzhou) Co., Ltd.'s application for drug registration for levosartamol hydrochloride atomized inhalation solution (hereinafter referred to as “this drug”) was approved by the State Drug Administration. The approved indication is for treating or preventing bronchospasm caused by reversible airway obstructive diseases in adults and children aged 6 and above.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.